ArticleOncotarget2017
Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.Gastroenterology · 2026Guideline
- HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.Virology journal · 2023Pooled it
- Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.Annals of medicine · 2026Article
- ALPS-HCC Score: A Dynamic Liver Stiffness Measurement-Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Machine Learning Model for Predicting Hepatocellular Carcinoma Development in Patients With Hepatitis B Virus-Related Cirrhosis Receiving Antiviral Therapy.The Kaohsiung journal of medical sciences · 2026Article
- Score-based prediction model for female hepatocellular carcinoma surveillance in asymptotic HBsAg carriers: a multicenter cohort study in China.Journal of the National Cancer Center · 2025Article
- Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C.Journal of gastroenterology and hepatology · 2025Article
- Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues.Journal of viral hepatitis · 2025Article
- Behaviour-Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER).Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Current and new strategies for hepatocellular carcinoma surveillance.Gastroenterology report · 2025Review
- Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma.Journal of liver cancer · 2024Article
- Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis B patients with cirrhosis.American journal of cancer research · 2024Article
- Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.Journal of clinical and translational hepatology · 2023Review
- Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.Clinical and molecular hepatology · 2023Review
- Prediction Model withInternational journal of molecular sciences · 2023Article
- Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study.Frontiers in pharmacology · 2023Article
- Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy.American journal of cancer research · 2023Article
- Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection.Clinical and molecular hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUntil now, no risk score could predict hepatocellular carcinoma (HCC) in nucleos(t)ide analog (NA)-treated Asian patients.
methodsWe enrolled 1325 NA-naïve chronic hepatitis B patients with entecavir monotherapy for >12 months, with 883 and 442 patients randomly assigned to the development and validation groups, respectively, in the risk model.
resultsThe cumulative probabilities of HCC were 2.4%, 4.1%, and 9.9% after 2, 3, and 5 years of treatment, respectively. In the development group, age, platelet counts, and alpha-fetoprotein levels after 12 months of treatment were the independent predictors of HCC. We converted the Cox proportional hazards regression coefficients for these predictors into risk scores and developed the APA-B model, with the total risk scores ranging from 0 to 15. The risk scores accurately categorized patients with low (0-5), medium (6-9), and high (10-15) risks in the validation group (
conclusionThe proposed HCC risk prediction model exhibited excellent predictive accuracy in NA-naïve Asian patients receiving entecavir therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.